Friday, 16 October 2026European Markets

AKER BP And ESSO Have A High Dividend Yield And Return On Equity In The Energy Sector.

Loading stream...

(vianews) - aker bp (akrbp.ol) is among this list of stock assets with the highest dividend rate and return on equity on the energy sector.

financial asset price forward dividend yield return on equity
aker bp (akrbp.ol) kr276.00 7.89% 11.97%
esso (es.pa) €53.85 3.98% 55.55%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. aker bp (akrbp.ol)

7.89% forward dividend yield and 11.97% return on equity

aker bp asa explores for, develops, and produces oil and gas on the norwegian continental shelf. the company was formerly known as det norske oljeselskap asa and changed its name to aker bp asa in october 2016. aker bp asa was founded in 2001 and is headquartered in fornebu, norway.

earnings per share

as for profitability, aker bp has a trailing twelve months eps of kr21.44.

pe ratio

aker bp has a trailing twelve months price to earnings ratio of 12.87. meaning, the purchaser of the share is investing kr12.87 for every norwegian krone of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.97%.

moving average

aker bp's value is above its 50-day moving average of kr266.00 and below its 200-day moving average of kr282.89.

volatility

aker bp's last week, last month's, and last quarter's current intraday variation average was 1.07%, 0.50%, and 1.56%.

aker bp's highest amplitude of average volatility was 2.35% (last week), 1.46% (last month), and 1.56% (last quarter).

more news about aker bp.

2. esso (es.pa)

3.98% forward dividend yield and 55.55% return on equity

esso s.a.f. refines, distributes, and markets refined petroleum products in france and internationally. the company's refining products include gas, gasoline, fuels and combustibles, and bitumens; petrochemical products, such as steam cracking, intermediate products, polyethylene, polypropylene, escorez, additives for petroleum products, and vistalon. it also manufactures and sells base oils, finished lubricants, white oils, and paraffins. in addition, the company operates a network of service stations under the esso and esso express brands, as well as provides greases. it offers fuels under the esso brand name and lubricants under the mobil brand. the company markets its products through a network of authorized distributors, resellers, and directly to industrial accounts. esso s.a.f. was founded in 1902 and is headquartered in nanterre, france. esso s.a.f. is a subsidiary of exxonmobil france holding s.a.s.

earnings per share

as for profitability, esso has a trailing twelve months eps of €55.9.

pe ratio

esso has a trailing twelve months price to earnings ratio of 0.96. meaning, the purchaser of the share is investing €0.96 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 55.55%.

volume

today's last reported volume for esso is 18869 which is 142.96% above its average volume of 7766.

yearly top and bottom value

esso's stock is valued at €53.85 at 02:30 est, way under its 52-week high of €68.40 and way higher than its 52-week low of €37.10.

more news about esso.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com